-

01:25:22 AM

QGEN Stock News

QGEN - Qiagen NV

04/21/21 1:00 AM

NYSE : QGEN

partnership

QIAGEN, in partnership with DiaSorin, announces the launch of the new LIAISON® LymeDetect® Assay based on QuantiFERON technology in countries accepting CE Mark for early diagnosis of Lyme Borreliosis

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the launch of the LIAISON ® LymeDetect ® Assay for markets accepting the CE Mark, as an aid to detect early Lyme Borreliosis infection (Lyme) on LIAISON ® analyzer systems.Lyme is a tick-borne

RHEA-AI

neutral

04/20/21 4:05 PM

NYSE : QGEN

QIAGEN Launches artus Prep&Amp as CE-Marked SARS-CoV-2 Test Offering up to Threefold Increase in Daily Lab Testing Capacity

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the artus ® SARS-CoV-2 Prep&Amp UM Kit which uses a liquid based sample preparation technology to simplify and increase COVID-19 testing throughput. The artus ® SARS-CoV-2 Prep&Amp UM Kit has been CE-IVD registered for

RHEA-AI

neutral

04/20/21 5:55 AM

NYSE : QGEN

conferences

QIAGEN N.V. to Report First Quarter 2021 Results

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced today that it plans to release its report on results for the first quarter 2021 on Monday, May 3, at approximately 22:05 Central European Time (CET) / 16:05 Eastern Daylight Time (EDT).A conference call is planned for Tuesday, May

RHEA-AI

neutral

04/06/21 4:05 PM

NYSE : QGEN

covid-19

QIAGEN Adds to COVID-19 Portfolio With New Ultra-Fast Sequencing Solution for High-Throughput Genomic Surveillance

QIAGEN N.V. (NYSE:QGEN; Frankfurt Prime Standard:QIA) today announced the launch of QIAseq DIRECT SARS-CoV-2 Kit, a viral genome enrichment and library preparation solution that significantly reduces library turnaround times and plastics use compared with ARTIC project protocols (primer-based

RHEA-AI

neutral

03/29/21 2:00 AM

NYSE : QGEN

covid-19

QIAGEN Receives FDA Emergency Use Authorization for NeuMoDx Multiplex Test Expanding COVID-19 Portfolio

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the Emergency Use Authorization by the U.S. FDA for the NeuMoDx™ Flu A-B/RSV/SARS-CoV-2 Vantage Assay that will help healthcare professionals quickly identify and differentiate individuals suspected by a healthcare provider of

RHEA-AI

neutral

03/05/21 6:05 AM

NYSE : QGEN

QIAGEN Announces 20-F Annual Report Filing for 2020 Results

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2020, with the U.S. Securities and Exchange Commission. The document can be accessed on

RHEA-AI

neutral

03/03/21 4:10 PM

NYSE : QGEN, QIA

QIAGEN Launches QIAsphere Cloud-Based Connectivity Solution to Enhance QIAstat-Dx Capabilities in Digital Diagnostics

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week.QIAsphere sets new standards for syndromic testing digital health, providing

RHEA-AI

neutral

03/02/21 4:11 PM

NYSE : QGEN, QIA

QIAGEN Launches QIAcube Connect MDx Platform for Automated Sample Processing in Diagnostic Labs

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of the QIAcube Connect MDx, a flexible platform for automated sample processing that will now be available to molecular diagnostic laboratories in the U.S. and Canada, the European Union and other markets

RHEA-AI

neutral

02/24/21 1:45 AM

NYSE, Nasdaq : QGEN, QIA, INO

QIAGEN and INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100 for Advanced Cervical Dysplasia

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology

RHEA-AI

very positive

02/24/21 1:45 AM

Nasdaq, NYSE : INO, QGEN

high short

INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO's VGX-3100 for advanced cervical dysplasia

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid

RHEA-AI

very positive

Prev 1 2 3 4 5 6 7 8 9 Next

QGEN Data

IndustryBiological Product (except Diagnostic) Manufacturing
Websitewww.qiagen.com
CeoThierry Bernard
Security nameQiagen NV
Issue typecs
SectorManufacturing
Sic code2836
Employees5610
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Biological Product (except Diagnostic) Manufacturing
AddressHulsterweg 82
StateLimburg
CityVenlo
Zip5912 PL
CountryNetherlands
Phone31773556600

About Qiagen NV

QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31, 2020, QIAGEN employed more than 5,600 people in over 35 locations worldwide.